DXB vs OPT pre release

Hey team,

Prior to OPTs August 2019 announcement, were patients that were the subject of the Phase 2 studies being treated through the Special Access Scheme and were prescribing doctors requesting their patients to remain on the product after the study finished (i.e. they they were already realising benefits which is why they requested this).

I am attemtping to draw some analogies between the sentiment and status quo just prior to OPTs result release announcement (what a glorious time it would have been) to DXBs current story.

Any direction greatly appreciated.

Cheers

Sand Stone